51388-00-2

Usage

Uses

Used in Pharmaceutical Industry:
N-2-aminoethyl homopiperidine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel drug molecules. Its presence in the molecular structure can enhance the pharmacological properties of the final product, making it a valuable component in drug discovery and design.
Used in Agrochemical Industry:
In the agrochemical sector, N-2-aminoethyl homopiperidine is utilized as a building block in the creation of pesticides and other agrochemicals. Its incorporation can lead to the development of more effective and safer products for agricultural use, contributing to increased crop yields and protection against pests.
Used in Anticancer Research:
N-2-aminoethyl homopiperidine has been studied for its potential as an anticancer agent. Its unique chemical structure may allow it to interact with biological targets in ways that could inhibit the growth and proliferation of cancer cells, offering a new avenue for cancer treatment.
Used in Neurological Disorder Treatment:
Research has also explored the role of N-2-aminoethyl homopiperidine in the treatment of neurological disorders. Its potential to modulate specific neurological pathways or interact with neurotransmitter systems positions it as a candidate for the development of therapeutics aimed at alleviating symptoms or slowing the progression of certain neurological conditions.

Upstream product

• 54714-50-0 N-cyanomethylperhydroazepine 
• 64-17-5 ethanol 
• 629-03-8 1 ,6-dibromohexane 
• 107-15-3 ethylenediamine 
• 93111-55-8 N-(2-(Hexamethyleneimino)ethyl)propionamide 
• 2205-31-4 1-(2-chloroethyl)-1H-hexahydroazepine 
• 111-49-9 hexamethylene imine 
• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 77731-49-8 N-(2-hexahydroazepin-1-yl-ethyl)-N'-phenyl-urea 
• 92263-32-6 N-(2-hexahydroazepin-1-yl-ethyl)-N'-phenyl-thiourea 
• 1201219-11-5 perfluorophenyl 4-(4-(4-(5-(2-(azepan-1-yl)ethylcarbamoyl)-1-methyl-1H-pyrrol-3-ylcarbamoyl)benzoyl)benzamido)-1-methyl-1H-pyrrole-2-carboxylate 
• 1434246-45-3 N-(4-{[2-(azepan-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide 
• 1175146-65-2 1-(2-azidoethyl)azepane 
• 117518-08-8 N-[2-(hexahydro-1H-azepin-1-yl)ethyl]-4-phenyl-1-piperazinecarboxamide 
• 401817-20-7 N-(2-azepan-1-ylethyl)-N-{4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl}amine 
• 401817-19-4 N-(2-azepan-1-ylethyl)-N-(4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl)amine 

Relevant academic research and scientific papers

Selectivity Optimization of Substituted 1,2,3-Triazoles as α7 Nicotinic Acetylcholine Receptor Agonists

Three series of substituted anti-1,2,3-triazoles (IND, PPRD, and QND), synthesized by cycloaddition from azide and alkyne building blocks, were designed to enhance selectivity and potency profiles of a lead α7 nicotinic acetylcholine receptor (α7-nAChR) agonist, TTIn-1. Designed compounds were synthesized and screened for affinity by a radioligand binding assay. Their functional characterization as agonists and antagonists was performed by fluorescence resonance energy transfer assay using cell lines expressing transfected cDNAs, α7-nAChRs, α4β2-nAChRs, and 5HT3A receptors, and a fluorescence cell reporter. In the IND series, a tropane ring of TTIn-1, substituted at N1, was replaced by mono- and bicyclic amines to vary length and conformational flexibility of a carbon linker between nitrogen atom and N1 of the triazole. Compounds with a two-carbon atom linker optimized binding with Kds at the submicromolar level. Further modification at the hydrophobic indole of TTIn-1 was made in PPRD and QND series by fixing the amine center with the highest affinity building blocks in the IND series. Compounds from IND and PPRD series are selective as agonists for the α7-nAChRs over α4β2-nAChRs and 5HT3A receptors. Lead compounds in the three series have EC50s between 28 and 260 nM. Based on the EC50, affinity, and selectivity determined from the binding and cellular responses, two of the leads have been advanced to behavioral studies described in the companion article (DOI: 10.1021/acschemneuro.5b00059).

Solution-phase parallel synthesis of novel membrane-targeted antibiotics

The increase in the incidence of antibiotic-resistant infections is a major concern to healthcare workers and requires the development of novel antibacterial agents. Recently, we described a series of benzophenonecontaining antibiotics which displayed activity against antibiotic-resistant bacteria. We have shown that these agents function by disrupting the bacterial membrane. To further explore these compounds, a practical and efficient solution-phase parallel synthesis method was developed which allowed us to prepare combinatorial libraries of these agents. Using this method, we prepared 218 compounds in 58 reactions. All of the compounds were characterized by HPLC and MALDI-TOF mass spectrometry. Analysis of this library for antibacterial activity identified six compounds which displayed MTC values of 2.0 mg/T. against Staphylococcus aureus. Examination of the structure-function relationships of these agents revealed that cationic groups were required and that cyclic, aliphatic amines were crucial for activity. Using the information generated here, we speculate on how the various structural features of the molecule are necessary for the interaction with the bacterial membrane.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

Fused pyrazole derivatives bieng protein kinase inhibitors

Compounds of Formula (I): salts or solvates or physiologically functional derivatives thereof, wherein Z is CH or N, and R1, (R2, and R4 are various substituent groups, are protein kinase inhibitors.

Synthesis and structure-activity relationships of cetiedil analogues as blockers of the Ca2+-activated K+ permeability of erythrocytes

Cetiedil, [2-cyclohexyl-2-(3-thienyl)ethanoic acid 2-(hexahydro-1H-azepin-1-yl)ethyl ester], which blocks the intermediate calcium-activated potassium ion permeability (IKCa) in red blood cells, was used as a lead for investigating structure-ac

Indazolecarboxamides

Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT 4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT 4 receptor.

Nucleophilic Ring Opening of 2-Oxazolines with Amines: A Convenient Synthesis for Unsymmetrically Substituted Ethylenediamines

The reaction of 2-alkyl-2-oxazolines with alkyl- and arylamines was investigated.The acid-catalyzed nucleophilic ring opening of the 2-oxazolines yields N-(2-aminoethyl)carboxamides in good to excellent yields with secondary amines and hindered primary amines.The N-(2-aminoethyl)carboxamides were hydrolyzed under acidic or basic conditions to selectively yield unsymmetrically substituted ethylenediamines.